# Synergy CHC Corp. (SNYRQ) · Edgar & Edgarette company card

> Synergy CHC (SNYRQ) saw revenue fall 12.8% in FY2025 to $30 million, operating margin -27.8% against a 0.7% median for medicinal chemicals & botanical products, equity -228% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1562733 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/SNYRQ) · [JSON](https://www.pops4.com/boards/company/SNYRQ.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $30M |
| Revenue growth, 1 year | -12.8% |
| Revenue growth per year | -1.5% |
| Operating margin | -27.8% (prior year 16.7%) |
| Net margin | -40.6% |
| Operating cash flow | −$3M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $3M |
| Long-term debt | $25M |
| Total assets | $10M |
| Total equity | −$23M |
| Equity ÷ assets | -227.5% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -23.28 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed bankruptcy or receivership, late annual report notice, debt accelerated or triggered in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative; operating loss: a margin of -27.8% in FY2025; revenue is hard to predict: its 80% range is ±47%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $30.4M (FY2025), total debt $25.1M. Experience: revenue down 12.8% on the year, down 1.5% a year over 7 years; operating margin -27.8%, down from 16.7%. Soundness: equity -227.5% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $16.8M and $46.7M next year (method v4.1: its own 2-year record of growth weighed at 25% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $15.7M to $50.2M. A statistical range, not company guidance. Against peers (10 filers, $50M+ revenue, medicinal chemicals & botanical products): operating margin -27.8% against a 0.7% median; growth -12.8% against 1.7%.

Range logged 2026-09-25, receipt 854abf2bdd966e49, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 1.03 Bankruptcy or receivership: 1, latest 2026-09-08 ([filing](https://www.sec.gov/Archives/edgar/data/1562733/000121390026097802/0001213900-26-097802-index.htm))
- Item NT 10-K Late annual report notice: 1, latest 2026-04-01 ([filing](https://www.sec.gov/Archives/edgar/data/1562733/000121390026037819/0001213900-26-037819-index.htm))
- Item 3.01 Exchange listing notice or transfer: 3, latest 2026-09-16 ([filing](https://www.sec.gov/Archives/edgar/data/1562733/000121390026100556/0001213900-26-100556-index.htm))
- Item 2.04 Debt accelerated or triggered: 2, latest 2026-08-26 ([filing](https://www.sec.gov/Archives/edgar/data/1562733/000121390026093728/0001213900-26-093728-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-09-08 ([filing](https://www.sec.gov/Archives/edgar/data/1562733/000121390026097802/0001213900-26-097802-index.htm))

## Recent filings

- 8-K · filed 2026-09-16 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule · [filing](https://www.sec.gov/Archives/edgar/data/1562733/000121390026100556/0001213900-26-100556-index.htm)
- 8-K · filed 2026-09-08 · 1.03 Bankruptcy or Receivership; 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1562733/000121390026097802/0001213900-26-097802-index.htm)
- 8-K · filed 2026-08-26 · 2.04 Triggering Events That Accelerate a Financial Obligation · [filing](https://www.sec.gov/Archives/edgar/data/1562733/000121390026093728/0001213900-26-093728-index.htm)
- 8-K · filed 2026-08-21 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1562733/000121390026092335/0001213900-26-092335-index.htm)
- 8-K · filed 2026-08-11 · 2.04 Triggering Events That Accelerate a Financial Obligation · [filing](https://www.sec.gov/Archives/edgar/data/1562733/000121390026087826/0001213900-26-087826-index.htm)
- 8-K · filed 2026-07-29 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1562733/000121390026082791/0001213900-26-082791-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001562733.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1562733

## Cite

POPS4, Edgar & Edgarette: Synergy CHC Corp. (SNYRQ) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/SNYRQ. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.